For example, it is well documented that BRAF mutations are predictive of response to BRAF inhibitor monotherapy in melanoma, but not in colorectal carcinoma.69 A recently completed basket trial assessing the efficacy of the BRAF inhibitor Vemurafenib in multiple BRAF mutant solid tumours confirmed a variable response across different tumour types. This evidence concerns the gene BRAF and neoplasm.